FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2485655499> ?p ?o ?g. }

• W2485655499 endingPage "68963" @default.
• W2485655499 startingPage "68950" @default.
• W2485655499 abstract "// Iván Alvarez-Twose 1, 5 , Almudena Matito 1, 5 , José Mário Morgado 1, 5 , Laura Sánchez-Muñoz 1, 5 , María Jara-Acevedo 2, 5 , Andrés García-Montero 2, 5 , Andrea Mayado 2, 5 , Carolina Caldas 2, 5 , Cristina Teodósio 3 , Javier Ignacio Muñoz-González 2, 5 , Manuela Mollejo 4, 5 , Luis Escribano 2, 5 and Alberto Orfao 2, 5 1 Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Hospital Virgen del Valle, Toledo, Spain 2 Centro de Investigación del Cáncer/IBMCC (USAL/CSIC) and IBSAL, Departamento de Medicina and Servicio General de Citometría, University of Salamanca, Salamanca, Spain 3 Department of Immunology, Erasmus Medical Center, University of Rotterdam, Rotterdam, The Netherlands 4 Department of Pathology, Hospital Virgen de la Salud, Toledo, Spain 5 Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain Correspondence to: Iván Alvarez-Twose, email: ivana@sescam.jccm.es Keywords: mast cell, mastocytosis, well-differentiated systemic mastocytosis, imatinib, KIT Received: March 01, 2016      Accepted: May 29, 2016      Published: July 19, 2016 ABSTRACT Resistance to imatinib has been recurrently reported in systemic mastocytosis (SM) carrying exon 17 KIT mutations. We evaluated the efficacy and safety of imatinib therapy in 10 adult SM patients lacking exon 17 KIT mutations, 9 of which fulfilled criteria for well-differentiated SM (WDSM). The World Health Organization 2008 disease categories among WDSM patients were mast cell (MC) leukemia ( n = 3), indolent SM ( n = 3) and cutaneous mastocytosis ( n = 3); the remainder case had SM associated with a clonal haematological non-MC disease. Patients were given imatinib for 12 months –400 or 300 mg daily depending on the presence vs. absence of > 30% bone marrow (BM) MCs and/or signs of advanced disease–. Absence of exon 17 KIT mutations was confirmed in highly-purified BM MCs by peptide nucleic acid-mediated PCR, while mutations involving other exons were investigated by direct sequencing of purified BM MC DNA. Complete response (CR) was defined as resolution of BM MC infiltration, skin lesions, organomegalies and MC-mediator release-associated symptoms, plus normalization of serum tryptase. Criteria for partial response (PR) included ≥ 50% reduction in BM MC infiltration and improvement of skin lesions and/or organomegalies. Treatment was well-tolerated with an overall response rate of 50%, including early and sustained CR in four patients, three of whom had extracellular mutations of KIT , and PR in one case. This later patient and all non-responders ( n = 5) showed wild-type KIT . These results together with previous data from the literature support the relevance of the KIT mutational status in selecting SM patients who are candidates for imatinib therapy." @default.
• W2485655499 created "2016-08-23" @default.
• W2485655499 creator A5011977184 @default.
• W2485655499 creator A5035827683 @default.
• W2485655499 creator A5044395832 @default.
• W2485655499 creator A5050521953 @default.
• W2485655499 creator A5052953804 @default.
• W2485655499 creator A5060849622 @default.
• W2485655499 creator A5063734569 @default.
• W2485655499 creator A5074588665 @default.
• W2485655499 creator A5076091594 @default.
• W2485655499 creator A5081652511 @default.
• W2485655499 creator A5082930849 @default.
• W2485655499 creator A5086153083 @default.
• W2485655499 creator A5088409474 @default.
• W2485655499 date "2016-07-19" @default.
• W2485655499 modified "2023-10-18" @default.
• W2485655499 title "Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 <i>KIT</i> mutations and review of the literature" @default.
• W2485655499 cites W1494664247 @default.
• W2485655499 cites W1555794478 @default.
• W2485655499 cites W1593000383 @default.
• W2485655499 cites W1803135625 @default.
• W2485655499 cites W1845165897 @default.
• W2485655499 cites W1963840931 @default.
• W2485655499 cites W1964608118 @default.
• W2485655499 cites W1965225129 @default.
• W2485655499 cites W1965854134 @default.
• W2485655499 cites W1969176159 @default.
• W2485655499 cites W1970155654 @default.
• W2485655499 cites W1974100080 @default.
• W2485655499 cites W1975240950 @default.
• W2485655499 cites W1975842834 @default.
• W2485655499 cites W1977786271 @default.
• W2485655499 cites W1979635877 @default.
• W2485655499 cites W1981899430 @default.
• W2485655499 cites W1982659189 @default.
• W2485655499 cites W1985792673 @default.
• W2485655499 cites W1988821060 @default.
• W2485655499 cites W1993327121 @default.
• W2485655499 cites W1997177551 @default.
• W2485655499 cites W1998340990 @default.
• W2485655499 cites W1999304658 @default.
• W2485655499 cites W2012975549 @default.
• W2485655499 cites W2015015957 @default.
• W2485655499 cites W2020085141 @default.
• W2485655499 cites W2022452901 @default.
• W2485655499 cites W2029908863 @default.
• W2485655499 cites W2029915657 @default.
• W2485655499 cites W2032682785 @default.
• W2485655499 cites W2035219932 @default.
• W2485655499 cites W2038961612 @default.
• W2485655499 cites W2041643615 @default.
• W2485655499 cites W2045888587 @default.
• W2485655499 cites W2046632940 @default.
• W2485655499 cites W2047665795 @default.
• W2485655499 cites W2054178052 @default.
• W2485655499 cites W2056727156 @default.
• W2485655499 cites W2060637213 @default.
• W2485655499 cites W2063045032 @default.
• W2485655499 cites W2067847647 @default.
• W2485655499 cites W2075904639 @default.
• W2485655499 cites W2077103177 @default.
• W2485655499 cites W2078398386 @default.
• W2485655499 cites W2086124901 @default.
• W2485655499 cites W2092784580 @default.
• W2485655499 cites W2095226581 @default.
• W2485655499 cites W2107058988 @default.
• W2485655499 cites W2109331088 @default.
• W2485655499 cites W2111914345 @default.
• W2485655499 cites W2117953011 @default.
• W2485655499 cites W2118229594 @default.
• W2485655499 cites W2126677578 @default.
• W2485655499 cites W2130683521 @default.
• W2485655499 cites W2133659914 @default.
• W2485655499 cites W2134318552 @default.
• W2485655499 cites W2137549989 @default.
• W2485655499 cites W2144031099 @default.
• W2485655499 cites W2147181024 @default.
• W2485655499 cites W2156349878 @default.
• W2485655499 cites W2165720262 @default.
• W2485655499 cites W2281555888 @default.
• W2485655499 cites W2329648702 @default.
• W2485655499 cites W570387683 @default.
• W2485655499 cites W593231466 @default.
• W2485655499 cites W7456156 @default.
• W2485655499 doi "https://doi.org/10.18632/oncotarget.10711" @default.
• W2485655499 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5620310" @default.
• W2485655499 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28978170" @default.
• W2485655499 hasPublicationYear "2016" @default.
• W2485655499 type Work @default.
• W2485655499 sameAs 2485655499 @default.
• W2485655499 citedByCount "69" @default.
• W2485655499 countsByYear W24856554992017 @default.
• W2485655499 countsByYear W24856554992018 @default.
• W2485655499 countsByYear W24856554992019 @default.
• W2485655499 countsByYear W24856554992020 @default.
• W2485655499 countsByYear W24856554992021 @default.
• W2485655499 countsByYear W24856554992022 @default.

• next